Literature DB >> 1747021

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course.

W S Fenton1, T H McGlashan.   

Abstract

The natural history and long-term course of schizophrenia divided by pervasiveness of positive and negative symptoms was explored among 187 schizophrenic patients from the Chestnut Lodge follow-up study. Schizophrenia with many negative symptoms was associated with poor premorbid functioning, insidious onset, partial or no remissions during the first several years of illness, and in most cases a progressive course leading to permanent disability. Schizophrenia with few negative symptoms was associated with good premorbid functioning, acute onset, intermittent early course, and a better prognosis. Positive symptoms predicted future hospitalizations but were less powerful and specific as indicators of differential illness history, course, and long-term functional incapacity. As predictors of long-term outcome, negative symptoms were of greater value measured at index admission several years after illness onset than at first hospital admission. Multivariate analyses indicated that two negative symptoms (anhedonia and affective flattening) contribute significantly to outcome variance independent of their association with premorbid functioning or positive symptoms. Patients with the poorest long-term outcome tended to show an increase in negative symptoms during the early years of their illness. Progressive negative symptoms early in the course of schizophrenia may thus reflect or signal a process leading to long-term functional disability.

Entities:  

Mesh:

Year:  1991        PMID: 1747021     DOI: 10.1001/archpsyc.1991.01810350018003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  54 in total

1.  Chronicity reconsidered: improving person-environment fit through a consumer-run service.

Authors:  M J Chinman; R Weingarten; D Stayner; L Davidson
Journal:  Community Ment Health J       Date:  2001-06

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 3.  Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

Review 4.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

5.  Probing the Dynamic Updating of Value in Schizophrenia Using a Sensory-Specific Satiety Paradigm.

Authors:  James A Waltz; Jaime K Brown; James M Gold; Thomas J Ross; Betty J Salmeron; Elliot A Stein
Journal:  Schizophr Bull       Date:  2015-04-01       Impact factor: 9.306

6.  Predictors of quality of life in schizophrenia.

Authors:  Jean Caron; Yves Lecomte; Emmanuel Stip; Suzanne Renaud
Journal:  Community Ment Health J       Date:  2005-08

7.  Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.

Authors:  Thomas H McGlashan; William T Carpenter
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

8.  Temperament and character as schizophrenia-related endophenotypes in non-psychotic siblings.

Authors:  Matthew J Smith; C Robert Cloninger; Michael P Harms; John G Csernansky
Journal:  Schizophr Res       Date:  2008-08-21       Impact factor: 4.939

9.  The power to resist: the relationship between power, stigma, and negative symptoms in schizophrenia.

Authors:  Timothy R Campellone; Janelle M Caponigro; Ann M Kring
Journal:  Psychiatry Res       Date:  2013-11-26       Impact factor: 3.222

10.  Measurement of problems in activities and participation in patients with anxiety, depression and schizophrenia using the ICF checklist.

Authors:  Rosalía Tenorio-Martínez; María del Carmen Lara-Muñoz; María Elena Medina-Mora
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-01-27       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.